Express News Service
PUDUCHERRY: Puducherry Lt Governor Dr. Tamilisai Soundararajan got some sample ‘2-DG’ drugs, the indigenously developed anti-Covid-19 drug, 2-deoxy-D-glucose or ‘2-DG’ from Telangana to Puducherry on Tuesday
The 2-DG drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Hyderabad-based pharma company Dr Reddy’s Laboratories (DRL).
The drug is effective and Covid patients improved symptomatically and became free from supplemental oxygen dependence, said Dr. Tamilisai Soundararajan, who herself is a medico.
The medicine which is given for 10 days, provided an early relief from oxygen dependence gradually after four days. Stating that she has held discussions through video conferencing with the producers and requested them to provide the medicine to Puducherry when it is made available in all states in a week or two.
'DRDO's drug was effective on brain cancer patients, can't say about Covid-19'
DRDO’s drug was first used in a human clinical study on brain tumour patients by Dr A K Banerji at AIIMS, Delhi, along with Dr Viney Jain, former director of INMAS LAB.
Share Via Email
| A+A A-
Dr AK Banerji who served at AIIMS' neurosurgery department for 30 years, said that the drug was reasonably effective on cancer.
Express News Service
NEW DELHI: Oral anti-viral drug 2-deoxy-D-glucose (2-DG), developed by the DRDO and being touted as a potential game-changer in the battle against Covid-19, was first used in a human clinical study on brain tumour patients by Dr A K Banerji at AIIMS, Delhi, along with Dr Viney Jain, former director of INMAS LAB (DRDO).
Fact Check: False information about immediate procurement of anti-coved drug 2-DG goes viral, Dr Reddy's clarifies
A message was recently circulating on social media claiming those in need of the 2-DG drug can request their hospital to place an order with Dr. Reddy'S Lab. The post also contains two e-mail IDs, purportedly of Dr. Reddy's Lab, and a list of personal details that the patients need to be provide while placing the order.
advertisement
UPDATED: May 22, 2021 17:56 IST
Dr. Reddy's clarified that the commercial launch and supply of 2-DG to major government and private hospitals is expected to commence only in mid-June 2021.
DRDO develops antibody test kit DIPCOVAN for early detection of COVID-19
DRDO develops antibody test kit DIPCOVAN for early detection of COVID-19
ANI / Updated: May 21, 2021, 17:05 IST
DRDO) has developed an
COVID.
DIPCOVAN, the DIPAS-VDx COVID 19 IgG Antibody Microwell ELISA for sero-surveillance has been developed by the Defence Institute of Physiology and Allied Sciences (DIPAS) in association with Delhi-based firm Vanguard Diagnostics Pvt Ltd.
According to DRDO, the kit can detect spike as well as nucleocapsid (S and N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent. It was developed indigenously by scientists, followed by extensive validation on over 1000 patient samples at various COVID hospitals in Delhi.
Kerala extends Covid lockdown till May 30, triple lockdown to continue only in Malappuram
Though there was a drop in the number of cases, Friday recorded the highest death of 142 when the day confirmed 29,673 new Covid cases.
Share Via Email
| A+A A-
A resident waiting to enter into the containment zone near Salim Rajan Road as police closed the entrance due to triple lockdown rules. (Photo | Albin Mathew, EPS) By Express News Service
THIRUVANANTHAPURAM: The Kerala government has decided to extend the lockdown enforced in the state till May 30. While the triple lockdown clamped in Thiruvananthapuram, Ernakulam, Thrissur will be withdrawn from Saturday, but it will remain in force in Malappuram due to the high test positivity rate (TPR) in the district.
The generic drugmaker released a statement on social media saying the anti-COVID remedy oral drug 2DG has not yet been launched into the market. Here, we advise our readers to remain vigilant and refrain themselves from falling into the trap of black marketers who lure them by offering the 2DG drug in exchange for a hefty amount. We request you to share this article with your friends and relative so as to alert your surroundings.
Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally.
New Delhi:
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute's Acharya Balkrishna as the lead author.
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
India's first indigenous anti-COVID drug 2-DG is a 'repurposed' medicine, the Indian Council of Medical Research said on Thursday. According to ICMR DG Dr. Balram Bhargava, the drug was earlier used for cancer treatment.